A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes

NCT02254291 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

308

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: semaglutide
DRUG: semaglutide
DRUG: sitagliptin

Sponsor

Novo Nordisk A/S